The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.

Edwards Lifesciences (NYSE: EW) today shared new data demonstrating successful outcomes with its mitral and tricuspid ...

Venus Medtech's Cardiovalve subsidiary announced today that it completed enrollment in a study of its tricuspid valve ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter tricuspid valve replacement in patients with trans-tricuspid valve pacemaker leads without ...

Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm ...

The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China , Oct.

IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the first transcatheter tricuspid valve replacement system. The system is indicated for ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S.

OR YEHUDA, Israel--(BUSINESS WIRE)--Cardiovalve announced today that it has received U.S. Food and Drug Administration (FDA) approval for an Early Feasibility Study (EFS) of its Transcatheter ...

Real-world data accumulated in Europe outside of a clinical trial support both the safety and the benefit of two transcatheter edge-to-edge (TEER) devices designed specifically for the treatment of ...